Anti-LIN28B Antibody (6R683) is a Rabbit antibody targeting LIN28B. Anti-LIN28B Antibody (6R683) can be used in WB,ICC/IF,IP,FCM.

IgG

6R683

Human

1. The HepG2 (H) cells were fixed with 4% PFA (10 min at r. T.) and then permeabilized with 90% ice-cold methanol for 20 min at -20℃, the cells then were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r. T.). Primary Antibody (green): Rabbit Anti-LIN28B antibody (TMAB-08318, 1: 100); Secondary Antibody (white blue): Goat anti-Rabbit IgG-BF488 (BF488): 1 μg/test. Blank control (black): PBS. Acquisition of 20,000 events was performed.
2. 25 ug total protein per lane of various lysates (see on figure) probed with LIN28B monoclonal antibody, unconjugated (TMAB-08318) at 1: 1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.

WB: 1:500-2000; ICC/IF: 1:50-200; IP: 1:20-50; FCM: 1:50-100

Monoclonal

A synthesized peptide: human Lin 28B

Human

LIN28B

Protein lin-28 homolog B

Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.